The medication lecanemab was approved by the U.S. FDA to treat Alzheimer’s disease in 2023. Like all medications, lecanemab ...

New data show that lecanemab is well tolerated outside of clinical trial setting, with expected and manageable side effects.

Patients in the earliest stage of Alzheimer disease, with very mild symptoms, experienced the lowest risk of complications ...

Lecanemab, the disease-modifying drug which can slow down the progression of Alzheimer’s disease, is set to be one of the most sought-after medications in the country after UK regulators ...

In 2023, the Food and Drug Administration (FDA) approved lecanemab, a new therapy for Alzheimer’s disease. This approval ...

Adoption of lecanemab, a novel infusion treatment for Alzheimer’s disease (AD), has been disproportionately higher among ...

Access to a new Alzheimer’s treatment, lecanemab, shows major disparities tied to race, gender, and income. Disparities in ...

Rural Georgians may find it difficult to access medication that could slow the progression of Alzheimer's disease, according ...

A recent study from the University of Georgia found that no rural counties had a PET scan facility, which is used to diagnose ...

I had just broken a story in Science about the horrific death of a volunteer in a trial of lecanemab, a much-anticipated new drug to treat Alzheimer’s by flushing certain dangerous substances ...

Viehbacher, “Biogen”) announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi ® (lecanemab) Marketing Authorization (MA) in the ...

Treatment with lecanemab infusion was safe and generally well-tolerated within an outpatient memory clinic setting, with few infusion-related reactions and a low number of withdrawals due to adverse ...